Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

25 June 2022

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

9 June 2022

Immunocore Appoints Siddharth Kaul to its Board of Directors

8 June 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

6 June 2022

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

3 June 2022

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

1 June 2022

Immunocore to present at upcoming investor conferences

26 May 2022

Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

11 May 2022

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

7 April 2022

Immunocore to present at the 21st Annual Needham Healthcare Conference

4 April 2022

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 143

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2022 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd